Top 10 Psychedelics in the Treatment of Depression Papers

Rucker and colleagues recover the pre-prohibition literature on psychedelics for unipolar mood disorders. The review is important because it shows both the early therapeutic signal and the limits of older study designs, giving modern depression research a historical baseline.

This review of systematic reviews summarises the early modern evidence for serotonergic psychedelics across mood, anxiety, and substance-use disorders. It is useful because it highlights promise while clearly showing why larger and longer studies were still needed.

Zeifman and colleagues examine experiential avoidance as a possible pathway from psychedelic use to lower depression severity and suicidal ideation. The paper is interesting because it connects symptom change to a psychological process that therapy can directly target.

Davis, Barrett, and Griffiths test psychological flexibility as a bridge between acute psychedelic effects and later decreases in depression and anxiety. The study matters because it turns broad claims about insight into a measurable therapeutic mechanism.

This Johns Hopkins trial helped move psilocybin for major depression into mainstream clinical discussion. Even with an open-label design and small sample, it showed rapid, substantial symptom reductions after two supported psilocybin sessions and motivated larger trials.

Roseman and colleagues ask what kind of acute experience predicts improvement after psilocybin for treatment-resistant depression. The finding that oceanic boundlessness, rather than visual intensity, tracked outcomes sharpened the field's focus on psychological quality over spectacle.

This six-month follow-up extended the early psilocybin depression work beyond immediate response. It is useful because it showed that some benefits persisted, while also underlining the need for controlled studies and careful psychological support around dosing.

This brain-imaging paper helped frame psilocybin therapy as a possible reset of depressive brain dynamics. It is interesting because post-treatment connectivity changes, rather than only acute drug effects, were linked to later clinical response.

Mertens and colleagues examine how psilocybin may affect emotional processing in treatment-resistant depression. The paper focuses on amygdala and prefrontal connectivity, supporting the idea that therapy may involve restored emotional responsiveness rather than emotional blunting.

This controlled ayahuasca trial broadened the depression literature beyond psilocybin and ketamine. It is notable because a single supported ayahuasca session produced rapid antidepressant effects in treatment-resistant depression while adding data on safety and tolerability.